Explore your "genotype" with data discover the new blue sea in the big Data Age!

Your genes are worth more than you think.

Perhaps a lot of people can't stand the targeted ads that follow their Facebook status, Gmail content or web browsing record. But the future may have an update, can help advertisers more effective publicity products and services delivery mechanism, based on is not the other, is your "gene."

Miinome, a New American company, is now building a genetic platform that can filter the received ads according to the client's genetic makeup, and may resell the customer's DNA data to traders or research institutions for profit.

At present, this is still a concept, "," The last gene will certainly become the industry to consider one of the factors. "This is only a niche market, but there is a lot of room for growth," said Michael Schatz, a Quangang laboratory for Cold Spring Harbor Laboratory, the world's leading research institute. ”

"We provide the first human gene market that has a membership control mechanism that applies to the Platform for Action," he said. Paul Saarinen, Miinome's chief executive, said: "I believe we can translate people's genes into useful information, not just when you're sick!" ”

"Count" your genetic data.

Miinome uses an open application interface (API) to combine social data from Twitter, Facebook, and LinkedIn to get a personal "genetic profile".

To make it clearer, if you have male baldness, Miinome's calculus system can sniff out factors that accelerate hair loss, such as stress or smoking, from your social media postings. If you choose to expose the data to Miinome's corporate partners, you will later see ads for these issues, such as nicotine patches, meditation, yoga, and even the ads advertised by the spa industry.

Miinome will start internal tests this spring, mainly for gene storage and brokerage. Members can choose to collaborate with academic institutions, pharmaceutical companies or advertisers, and miinome guarantee that they will never peer into the original "genetic data" of their customers. Saarinen said that although the company is free to provide genetic services, but the business opportunities are still unlimited, because under such a mechanism, members than customers are actually more like goods. The old saying, no money is the most expensive!

Miinome will be charged according to the number of times a person sees a member's genes, and different genes will have different prices depending on the principle of supply and demand. For example, the price of a gene combination with lactose intolerance and Alzheimer's disease will be different.

Information security remains the biggest concern

Companies that used to sell "genetic data" may not have the option to let members decide how their data should be used, but miinome members can decide what to do with their partner. This is a good opportunity for research institutions to engage with participants, and many of the data that have been inaccessible to research in the past, such as living conditions or family history, are now available for use.

So Miinome's business model seems to solve the problem of people worrying about the misuse of their data, but we still don't know what the true value of these genetic data is. Are there any other security issues that might arise? What are the risks of sharing your genes with these private businesses? Will it have an impact on the family?

The key is that this type of gene broker should educate consumers on how to share their money securely, ensuring that on this platform, people can easily decide whether to share their genes, and that brokers should strictly keep the data out so they can build a secure network.

If you can get consumer trust, this is a good business model to look forward to.

(Responsible editor: The good of the Legacy)